Published in Drug Dev Res on October 15, 2014
Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. BMC Genomics (2016) 0.77
Effects of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine on visual signal detection performance in rats. Behav Pharmacol (2015) 0.76
Examining the reinforcement-enhancement effects of phencyclidine and its interactions with nicotine on lever-pressing for a visual stimulus. Behav Brain Res (2015) 0.75
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 10.97
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature (2011) 6.40
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol (2008) 3.90
Addictive drugs and brain stimulation reward. Annu Rev Neurosci (1996) 3.12
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc (2007) 2.63
A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76
Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res (2011) 1.62
Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex. J Neurosci (1996) 1.53
Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol (2013) 1.47
The effects of phencyclidine, ketamine, delta-amphetamine and pentobarbital on schedule-controlled behavior in the mouse. J Pharmacol Exp Ther (1976) 1.45
Tackling adolescent substance abuse in Hong Kong: where we should and should not go. ScientificWorldJournal (2007) 1.42
Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev (2014) 1.37
Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain (2009) 1.32
Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch Gen Psychiatry (1979) 1.22
5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. Eur Addict Res (2007) 1.20
Prediction of abuse liability of drugs using IV self-administration by rats. Psychopharmacology (Berl) (1984) 1.15
Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience (2009) 1.13
Self-stimulation and drug reward mechanisms. Ann N Y Acad Sci (1992) 1.12
Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev (2005) 1.06
DRL interresponse-time distributions: quantification by peak deviation analysis. J Exp Anal Behav (1993) 1.06
Substance use initiation: the role of simultaneous polysubstance use. Drug Alcohol Rev (2012) 1.03
Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol (1993) 1.00
Effects of fixed ratio size and dose on phencyclidine self-administration by rats. Psychopharmacology (Berl) (1989) 0.98
Social stimuli enhance phencyclidine (PCP) self-administration in rhesus monkeys. Pharmacol Biochem Behav (2007) 0.96
Different binding affinities of NMDA receptor channel blockers in various brain regions--indication of NMDA receptor heterogeneity. Neuropharmacology (1995) 0.94
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl) (2013) 0.91
Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2014) 0.90
Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs. J Pharmacol Exp Ther (1983) 0.89
Neurochemical and behavioural effects of acute and chronic memantine administration in rats: Further support for NMDA as a new pharmacological target for the treatment of depression? Brain Res Bull (2009) 0.89
Memantine treatment reverses anhedonia, normalizes corticosterone levels and increases BDNF levels in the prefrontal cortex induced by chronic mild stress in rats. Metab Brain Dis (2012) 0.88
Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology (2003) 0.88
Phencyclidine-induced potentiation of brain stimulation reward: acute effects are not altered by repeated administration. Psychopharmacology (Berl) (1993) 0.86
Effects of monoamine oxidase inhibitors on performance during differential reinforcement of low response rate. Psychopharmacology (Berl) (1982) 0.86
Comparison of phencyclidine and three analogues on fixed-interval performance in rhesus monkeys. Pharmacol Biochem Behav (1980) 0.85
The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology (Berl) (1999) 0.84
Effects of altering reinforcer magnitude and reinforcement schedule on phencyclidine (PCP) self-administration in monkeys using an adjusting delay task. Pharmacol Biochem Behav (2008) 0.84
Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment. Behav Pharmacol (2013) 0.83
The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. Behav Pharmacol (2007) 0.83
Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule. Behav Pharmacol (2014) 0.82
Animal models of intravenous phencyclinoid self-administration. Pharmacol Biochem Behav (1987) 0.81
Effects of phencyclidine, d-amphetamine and pentobarbital on schedule-controlled behavior in rats. Pharmacol Biochem Behav (1981) 0.81
The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther (1990) 0.80
Reductions in ethanol, phencyclidine, and food-maintained behavior by naltrexone pretreatment in monkeys is enhanced by open economic conditions. Psychopharmacology (Berl) (2000) 0.79
Interactions of naloxone with morphine, amphetamine and phencyclidine on fixed interval responding for intracranial self-stimulation in rats. Psychopharmacology (Berl) (1990) 0.78
Comparison of the behavioral effects of phencyclidine, ketamine, d-amphetamine and morphine in the squirrel monkey. J Pharmacol Exp Ther (1982) 0.78
Flesinoxan shows antidepressant activity in a DRL 72-s screen. Psychopharmacology (Berl) (1992) 0.78
Subchronic phencyclidine exposure potentiates the behavioral and c-Fos response to stressful stimuli in rats. Pharmacol Biochem Behav (2007) 0.78
Phencyclidine (PCP) self-administration and withdrawal in rhesus monkeys: effects of buprenorphine and dizocilpine (MK-801) pretreatment. Pharmacol Biochem Behav (1994) 0.77
Effects of phencyclidine, haloperidol, and naloxone on fixed-interval performance in rats. Psychopharmacology (Berl) (1984) 0.76
Intravenous self-administration of phencyclidine and related compounds in the dog. J Pharmacol Exp Ther (1982) 0.76
Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addict Behav (2004) 2.52
Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists. J Neurosci (2002) 1.80
Explaining the escalation of drug use in substance dependence: models and appropriate animal laboratory tests. Pharmacology (2007) 1.62
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. J Med Chem (2003) 1.62
Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev (2008) 1.46
Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology (2003) 1.35
Preclinical Determinants of Drug Choice under Concurrent Schedules of Drug Self-Administration. Adv Pharmacol Sci (2012) 1.34
Effects of pain- and analgesia-related manipulations on intracranial self-stimulation in rats: further studies on pain-depressed behavior. Pain (2009) 1.32
Development of a rationally designed, low abuse potential, biogenic amine releaser that suppresses cocaine self-administration. J Pharmacol Exp Ther (2005) 1.29
Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2003) 1.21
Cocaine versus food choice procedure in rats: environmental manipulations and effects of amphetamine. J Exp Anal Behav (2013) 1.19
Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats. J Pain (2013) 1.18
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav (2008) 1.17
Targeting pain-suppressed behaviors in preclinical assays of pain and analgesia: effects of morphine on acetic acid-suppressed feeding in C57BL/6J mice. J Pain (2006) 1.16
Targeting pain-depressed behaviors in preclinical assays of pain and analgesia: drug effects on acetic acid-depressed locomotor activity in ICR mice. Life Sci (2009) 1.13
Effect of gonadectomy and gonadal hormone replacement on cocaine self-administration in female and male rats. Neuropsychopharmacology (2004) 1.11
Effects of 14-day treatment with the schedule III anorectic phendimetrazine on choice between cocaine and food in rhesus monkeys. Drug Alcohol Depend (2013) 1.09
The selective non-peptidic delta opioid agonist SNC80 does not facilitate intracranial self-stimulation in rats. Eur J Pharmacol (2008) 1.09
Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys. Behav Pharmacol (2011) 1.08
Role of phenmetrazine as an active metabolite of phendimetrazine: evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys. Drug Alcohol Depend (2012) 1.06
Behavioral pharmacology of the mu/delta opioid glycopeptide MMP2200 in rhesus monkeys. J Pharmacol Exp Ther (2008) 1.03
Interaction between behavioral and pharmacological treatment strategies to decrease cocaine choice in rhesus monkeys. Neuropsychopharmacology (2012) 1.02
Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats. J Pharmacol Exp Ther (2005) 1.01
Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. J Pharmacol Exp Ther (2005) 1.01
Effects of extended cocaine access and cocaine withdrawal on choice between cocaine and food in rhesus monkeys. Neuropsychopharmacology (2010) 1.00
Dissociable effects of the cannabinoid receptor agonists Δ9-tetrahydrocannabinol and CP55940 on pain-stimulated versus pain-depressed behavior in rats. J Pharmacol Exp Ther (2012) 1.00
Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Br J Pharmacol (2014) 0.99
Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol (2010) 0.99
In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res (2008) 0.97
Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol (2004) 0.94
Role of µ-opioid receptor reserve and µ-agonist efficacy as determinants of the effects of µ-agonists on intracranial self-stimulation in rats. Behav Pharmacol (2012) 0.93
Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys. Pharmacol Biochem Behav (2006) 0.92
Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2014) 0.90
Effects of the delta-opioid agonist SNC80 on the abuse liability of methadone in rhesus monkeys: a behavioral economic analysis. Psychopharmacology (Berl) (2011) 0.90
Abuse-related effects of µ-opioid analgesics in an assay of intracranial self-stimulation in rats: modulation by chronic morphine exposure. Behav Pharmacol (2013) 0.89
Effects of d-amphetamine and buprenorphine combinations on speedball (cocaine+heroin) self-administration by rhesus monkeys. Neuropsychopharmacology (2007) 0.89
Antinociceptive interactions between Mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of Mu agonist efficacy. J Pharmacol Exp Ther (2010) 0.88
Effects of estradiol on cocaine self-administration and cocaine discrimination by female rhesus monkeys. Neuropsychopharmacology (2007) 0.87
Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys. J Pharmacol Exp Ther (2002) 0.86
Drug discrimination: 30 years of progress. Psychopharmacology (Berl) (2009) 0.85
Effects of the triple monoamine uptake inhibitor amitifadine on pain-related depression of behavior and mesolimbic dopamine release in rats. Pain (2015) 0.85
The effects of cocaine on gonadal steroid hormones and LH in male and female rhesus monkeys. Neuropsychopharmacology (2004) 0.84
Effects of the selective delta opioid agonist SNC80 on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol (2006) 0.84
Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: implications for abuse liability assessment. Behav Pharmacol (2013) 0.83
Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey. Pharmacol Biochem Behav (2009) 0.83
Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: Further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics. Pharmacol Biochem Behav (2010) 0.83
Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacol Biochem Behav (2006) 0.83
Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule. Behav Pharmacol (2014) 0.82
The effect of chronic amphetamine treatment on cocaine-induced facilitation of intracranial self-stimulation in rats. Psychopharmacology (Berl) (2014) 0.82
The effects of heroin on prolactin levels in male rhesus monkeys: use of cumulative-dosing procedures. Psychoneuroendocrinology (2002) 0.82
Serotonin receptor mechanisms mediate the discriminative stimulus properties of the atypical antipsychotic clozapine in C57BL/6 mice. Psychopharmacology (Berl) (2005) 0.81
Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain (2006) 0.81
Brief history of the Drug Evaluation Committee (DEC) and its role in the college on problems of drug dependence. Drug Alcohol Depend (2006) 0.81
Effects of the novel, selective and low-efficacy mu opioid receptor ligand NAQ on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2014) 0.80
Discriminative stimulus properties of the atypical antipsychotic drug clozapine in rats trained to discriminate 1.25 mg/kg clozapine vs. 5.0 mg/kg clozapine vs. vehicle. Behav Pharmacol (2006) 0.80
Effects of gender and menstrual cycle phase on food-maintained responding under a progressive-ratio schedule in cynomolgus monkeys. Pharmacol Biochem Behav (2006) 0.80
Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur J Pharmacol (2004) 0.79
Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice. Behav Pharmacol (2012) 0.78
Effects of kappa opioid agonists alone and in combination with cocaine on heart rate and blood pressure in conscious squirrel monkeys. Eur J Pharmacol (2007) 0.78
The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats. Psychopharmacology (Berl) (2008) 0.77
Further characterization of the discriminative stimulus properties of the atypical antipsychotic drug clozapine in C57BL/6 mice: role of 5-HT(2A) serotonergic and alpha (1) adrenergic antagonism. Psychopharmacology (Berl) (2008) 0.77
Cocaine-like discriminative stimulus effects of phendimetrazine and phenmetrazine in rats. Behav Pharmacol (2016) 0.77
Pharmacological modulation of neuropathic pain-related depression of behavior: effects of morphine, ketoprofen, bupropion and [INCREMENT]9-tetrahydrocannabinol on formalin-induced depression of intracranial self-stimulation in rats. Behav Pharmacol (2016) 0.77
Thr136Ile polymorphism of human vesicular monoamine transporter-1 (SLC18A1 gene) influences its transport activity in vitro. Neuro Endocrinol Lett (2012) 0.77
Effects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats. J Pharmacol Exp Ther (2015) 0.76
A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeys. Exp Clin Psychopharmacol (2013) 0.76
Effects of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine on visual signal detection performance in rats. Behav Pharmacol (2015) 0.76
Route of administration influences substitution patterns in rats trained to discriminate methadone vs. vehicle. Drug Alcohol Depend (2009) 0.76
Reply to: Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berl) (2014) 0.75
Role of 5-HT₂C receptors in effects of monoamine releasers on intracranial self-stimulation in rats. Psychopharmacology (Berl) (2015) 0.75
Oral modafinil facilitates intracranial self-stimulation in rats: comparison with methylphenidate. Behav Pharmacol (2017) 0.75
Ovarian steroid hormone modulation of the acute effects of cocaine on luteinizing hormone and prolactin levels in ovariectomized rhesus monkeys. J Pharmacol Exp Ther (2003) 0.75
The antidepressant drugs fluoxetine and duloxetine produce anxiolytic-like effects in a schedule-induced polydipsia paradigm in rats: enhancement of fluoxetine's effects by the α2 adrenoceptor antagonist yohimbine. Behav Pharmacol (2015) 0.75
The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL/6 mice. Behav Pharmacol (2011) 0.75
Clozapine and N-methyl-D-aspartate have positive modulatory actions on their respective discriminative stimulus properties in C57BL/6 mice. Eur J Pharmacol (2010) 0.75